PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: PIPELINE LANDSCAPE PART 08: MARKET SEGMENTATION BY MOLECULE TYPE • Segmentation by molecule type • Comparison by molecule type • Biologicals – Market size and forecast 2017-2022 • Small molecules – Market size and forecast 2017-2022 • Market opportunity by molecule type PART 09: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Rheumatology therapeutics market in the Americas • Rheumatology therapeutics market in EMEA • Rheumatology therapeutics market in APAC • Market opportunity PART 10: CUSTOMER LANDSCAPE PART 11: DECISION FRAMEWORK PART 12: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 13: MARKET TRENDS • Rising number of small molecules in the drug development pipeline • Strategic alliances • Increasing patient support programs PART 14: VENDOR LANDSCAPE • Overview • Landscape disruption PART 15: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • AbbVie • Amgen • Janssen Pharmaceuticals • Pfizer • UCB PART 16: APPENDIX • List of abbreviations     Exhibit 01: Parent market Exhibit 02: Global immunology therapeutics market segmentation Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition: Inclusions and exclusions checklist Exhibit 06: Market size 2017 Exhibit 07: Validation techniques employed for market sizing 2017 Exhibit 08: Global rheumatology therapeutics market – Market size and forecast 2017-2022 ($ mn) Exhibit 09: Global rheumatology therapeutics market – Year-over-year growth 2018-2022 (%) Exhibit 10: Five forces analysis 2017 Exhibit 11: Five forces analysis 2022 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition: Five forces 2017 Exhibit 18: Pipeline landscape by development phase 2017-2018 Exhibit 19: Some of the late-stage pipeline molecules in global rheumatology therapeutics market 2017-2018 Exhibit 20: Global rheumatology therapeutics market – Market share by molecule type 2017-2022 (%) Exhibit 21: Comparison by molecule type Exhibit 22: Global rheumatology therapeutics market by biologicals – Market size and forecast 2017-2022 ($ mn) Exhibit 23: Global rheumatology therapeutics market by biologicals – Year-over-year growth 2018-2022 (%) Exhibit 24: Global rheumatology therapeutics market by small molecules – Market size and forecast 2017-2022 ($ mn) Exhibit 25: Global rheumatology therapeutics market by small molecules – Year-over-year growth 2018-2022 (%) Exhibit 26: Market opportunity by molecule type Exhibit 27: Global rheumatology therapeutics market – Market share by geography 2017-2022 (%) Exhibit 28: Regional comparison Exhibit 29: Rheumatology therapeutics market in Americas – Market size and forecast 2017-2022 ($ mn) Exhibit 30: Rheumatology therapeutics market in the Americas – Year-over-year growth 2018-2022 (%) Exhibit 31: Top 3 countries in the Americas Exhibit 32: Rheumatology therapeutics market in EMEA – Market size and forecast 2017-2022 ($ mn) Exhibit 33: Rheumatology therapeutics market in EMEA – Year-over-year growth 2018-2022 (%) Exhibit 34: Top 3 countries in EMEA Exhibit 35: Rheumatology therapeutics market in APAC – Market size and forecast 2017-2022 ($ mn) Exhibit 36: Rheumatology therapeutics market in APAC – Year-over-year growth 2018-2022 (%) Exhibit 37: Top 3 countries in APAC Exhibit 38: Market opportunity Exhibit 39: Customer landscape Exhibit 40: Some of the discontinued pipeline molecules in global rheumatology therapeutics market Exhibit 41: Vendor landscape Exhibit 42: Landscape disruption Exhibit 43: Vendors covered Exhibit 44: Vendor classification Exhibit 45: Market positioning of vendors Exhibit 46: AbbVie – Overview Exhibit 47: AbbVie – Business segments Exhibit 48: AbbVie – Organizational developments Exhibit 49: AbbVie – Geographic focus Exhibit 50: AbbVie – Key offerings Exhibit 51: AbbVie – Key customers Exhibit 52: Amgen – Overview Exhibit 53: Amgen – Business segments Exhibit 54: Amgen – Organizational developments Exhibit 55: Amgen – Geographic focus Exhibit 56: Amgen – Key offerings Exhibit 57: Amgen – Key customers Exhibit 58: Janssen Pharmaceuticals – Overview Exhibit 59: Janssen Pharmaceuticals – Business segments Exhibit 60: Janssen Pharmaceuticals – Organizational developments Exhibit 61: Janssen Pharmaceuticals – Geographic focus Exhibit 62: Janssen Pharmaceuticals – Segment focus Exhibit 63: Janssen Pharmaceuticals – Key offerings Exhibit 64: Janssen Pharmaceuticals – Key customers Exhibit 65: Pfizer – Overview Exhibit 66: Pfizer – Business segments Exhibit 67: Pfizer – Organizational developments Exhibit 68: Pfizer – Geographic focus Exhibit 69: Pfizer – Segment focus Exhibit 70: Pfizer – Key offerings Exhibit 71: Pfizer – Key customers Exhibit 72: UCB – Overview Exhibit 73: UCB – Business segments Exhibit 74: UCB – Organizational developments Exhibit 75: UCB – Geographic focus Exhibit 76: UCB – Key offerings Exhibit 77: UCB – Key customers

AbbVie Amgen Janssen Pharmaceuticals Pfizer UCB